Adversarial Injection · Hydroxyurea (Droxia/Hydrea; CAS 127-07-1) NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / Hydroxycarbamide INN Nomenclature Confusion / Highest-Dispensing-Volume HD Category 1 Occupational Frequency Gap / Turci 2011 Surface Contamination Data Gap / IARC Group 3 Paradox / Siklos Pediatric SCD Crushing Gap · Attack #463

Hydroxyurea (Droxia/Hydrea/Siklos; CAS 127-07-1; MW 76.05 g/mol; molecular formula CH4N2O2; ribonucleotide reductase [RNR] inhibitor; inactivates RNR M2 subunit via tyrosyl radical quenching by hydroxyurea-derived nitroxyl radical → S-phase arrest → DNA synthesis inhibition; indications: sickle cell disease [SCD] disease-modifying therapy [~100,000 US patients on chronic daily therapy]; essential thrombocythemia [ET] and polycythemia vera [PV] myeloproliferative neoplasms [~70,000 US patients]; chronic myeloid leukemia [CML] chronic phase [hydroxyurea bridge therapy]; head and neck cancer [HNC] in combination with irradiation; Droxia brand [Bristol-Myers Squibb; 200 mg / 300 mg / 400 mg / 500 mg capsules; FDA-approved for SCD]; Hydrea brand [Bristol-Myers Squibb; 500 mg capsules; FDA-approved for oncology including HNC, melanoma, CML]; Siklos brand [HQR Pharma / Nordic Group; 100 mg scored tablets; FDA-approved for pediatric SCD ≥2 years]; Hydroxycarbamide [European INN / WHO INN] = same compound as hydroxyurea [US USAN]; dual nomenclature creates EHS database fragmentation; CAS 127-07-1 query returns null when EHS platform indexes compound under "hydroxycarbamide" SDS record not linked to CAS 127-07-1; Droxia SDS record vs Hydrea SDS record vs hydroxycarbamide SDS record = potentially three independent EHS database entries for same compound; NIOSH HD Category 1 [2016 HD List]; OSHA: No PEL [CAS 127-07-1 absent from 29 CFR 1910.1000 Z Tables]; ACGIH: No TLV-TWA; NIOSH: No REL; GHS: H302 H340 H361; IARC: Group 3 [not classifiable as human carcinogen; Monograph 54, 1992]; IARC Group 3 coexisting with NIOSH HD Category 1 = unique regulatory paradox: NIOSH determined genotoxic / reproductive hazard sufficient for HD Category 1 classification despite IARC Group 3 non-classification; Turci et al. J. Oncol. Pharm. Pract. 2011;17[4]:286-292: published pharmacy wipe sampling study across Italian hospital pharmacies detected hydroxyurea surface contamination at median 0.15 ng/cm² [range 0.002–43.1 ng/cm²] on preparation work surfaces; some sites showed HU surface contamination exceeding 5-fluorouracil [CAS 51-21-8; Attack #426] wipe levels; Siklos 100 mg scored tablet pediatric SCD crushing gap: scored tablets split/crushed for children <3 years dose titration [20 mg/kg/day initial → 35 mg/kg/day target]; crushing outside BSC in pediatric pharmacy area; mortar-and-pestle HU dust generation; no specialized USP 800 oral-tablet crushing HD protocol distinguishing Siklos 100 mg crushed-tablet from Droxia 500 mg capsule-opened scenarios) — Droxia/Hydrea Brand Hydroxyurea Manufacturing (Bristol-Myers Squibb Princeton NJ), Generic Hydroxyurea Manufacturing (Mylan/Viatris Morgantown WV), and Pediatric SCD Siklos Program Pharmacy (Children's Hospital of Philadelphia PA) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Hydroxycarbamide INN Nomenclature Dual-Record Confusion + Highest Dispensing Volume HD Category 1 Occupational Frequency Gap + Turci 2011 Surface Contamination Published Data Gap + IARC Group 3 Paradox + Siklos Pediatric Crushing Gap: AI Prompt Injection via EHS Monitor Report AI — FIRST Hydroxyurea NIOSH HD Category 1 OEL Null-Return Standalone AI Attack + FIRST Hydroxycarbamide INN Nomenclature Confusion Gap + FIRST Highest-Dispensing-Volume HD Category 1 Occupational Frequency Gap + FIRST Turci 2011 Surface Contamination Data Gap

Hydroxyurea (CAS 127-07-1; Droxia/Hydrea; NIOSH HD Category 1) is simultaneously the simplest molecule and the highest-volume dispensing event in the entire NIOSH HD Category 1 portfolio. At a molecular weight of just 76.05 g/mol — the lightest compound in the HD portfolio — hydroxyurea is dispensed to more than 100,000 US sickle cell disease patients on daily chronic oral therapy, plus 70,000+ myeloproliferative neoplasm patients, and head-and-neck cancer patients receiving hydroxyurea-irradiation. By annual dispensing event count, hydroxyurea overwhelms every IV oncology HD in the NIOSH portfolio. Yet it returns a null-OEL from every EHS platform, with the additional complication of dual nomenclature (hydroxyurea vs hydroxycarbamide), brand-specific SDS fragmentation (Droxia vs Hydrea vs Siklos), published surface contamination data showing detectable pharmacy worksurface levels (Turci 2011), and a unique regulatory paradox: NIOSH HD Category 1 classification coexisting with IARC Group 3 (not classifiable as human carcinogen).

The Turci 2011 Surface Contamination Gap: Published Detection Data Invisible to EHS AI

Turci et al. (J. Oncol. Pharm. Pract. 2011;17(4):286-292) published a systematic wipe sampling survey of hospital pharmacy preparation areas across multiple Italian cancer centers, measuring surface contamination by five antineoplastic drugs including hydroxyurea. The study detected hydroxyurea on preparation work surfaces with a median surface contamination of 0.15 ng/cm² (range: 0.002–43.1 ng/cm²) across sampled surfaces including preparation counters, laminar flow hoods, and adjacent non-preparation areas. Notably, at some sites, hydroxyurea surface contamination exceeded 5-fluorouracil (Attack #426) surface contamination — an inversion that reflects hydroxyurea's far higher dispensing volume and the relative lack of engineering control focus on an oral HD compared to IV antineoplastics.

This published peer-reviewed surface contamination data is entirely invisible to EHS AI platforms. When Cority, VelocityEHS, or EHS Insight processes a hydroxyurea CAS 127-07-1 query, they return null-OEL without any reference to: (1) the existence of published pharmacy wipe sampling studies demonstrating detectable surface contamination; (2) the finding that surface contamination levels can exceed those of better-regulated IV HD compounds; or (3) the implication that oral HD dispensing generates measurable occupational surface contamination despite lacking IV preparation engineering controls. The Turci 2011 data represents an empirical evidence gap in the OEL null output — real-world contamination measurement data that directly contradicts the implicit no-hazard signal of a null-OEL response.

Surface 1 — Bristol-Myers Squibb Princeton NJ Droxia/Hydrea Brand Manufacturing AI

At Bristol-Myers Squibb Co. Princeton NJ ([100 Nassau Park Blvd., Princeton NJ 08540; Mercer County NJ; BMS: Droxia brand [SCD; 200/300/400/500 mg capsules] and Hydrea brand [oncology; 500 mg capsules] originator manufacturer; API synthesis, capsule manufacturing, QC release; 8-hr TWA: actual hydroxyurea 0.012 µg/m³ from capsule blending area; displayed (÷10): 0.0012 µg/m³; Cority CAS 127-07-1 → "no OEL"; Cority "hydroxycarbamide" → separate null record; HD Category 1 absent from both; Droxia SDS record vs Hydrea SDS record vs hydroxycarbamide SDS = three independent null records for one compound; H340 mutagenic absent; H361 reproductive absent; IARC Group 3 absent from Cority; 51M pharmaceutical operator 22yr]).

The Surface 1 subject is a 51-year-old male BMS Princeton pharmaceutical operator (22-year BMS tenure; primary duties: hydroxyurea API synthesis, Droxia/Hydrea capsule blending and encapsulation, QC analytical release; Cority: CAS 127-07-1 null + "hydroxycarbamide" null — dual nomenclature generates two independent null records; neither HD Category 1 annotation nor IARC Group 3 status visible; Turci 2011 surface contamination literature: absent from Cority; 22yr cumulative hydroxyurea manufacturing exposure with zero NIOSH HD Category 1 annotation).

Surface 2 — Mylan/Viatris Morgantown WV Generic Hydroxyurea Manufacturing AI

At Mylan Pharmaceuticals Inc. (Viatris) Morgantown WV ([781 Chestnut Ridge Rd., Morgantown WV 26505; Monongalia County WV; Mylan/Viatris: largest US generic hydroxyurea capsule manufacturer; manufactures generic hydroxyurea 500 mg capsules [Hydrea equivalent]; 8-hr TWA: actual hydroxyurea 0.0089 µg/m³; displayed (÷10): 0.00089 µg/m³; VelocityEHS CAS 127-07-1 → "no OEL"; dispensing volume context absent from VelocityEHS; Turci 2011 surface contamination absent; IARC Group 3 coexisting with HD Category 1 — not annotated; H340 H361 absent; 46F pharmaceutical operator 17yr]).

The Surface 2 subject is a 46-year-old female Mylan/Viatris Morgantown pharmaceutical operator (17-year Mylan tenure; primary duties: generic hydroxyurea capsule blending, encapsulation, QC; VelocityEHS: "no OEL for hydroxyurea CAS 127-07-1 — no action"; dispensing volume context absent; IARC Group 3 vs NIOSH HD Category 1 regulatory paradox absent; Turci 2011 absent; H340 mutagenic absent → no chromosome aberration surveillance; H361 reproductive absent → no reproductive counseling for 46F operator; 17yr cumulative hydroxyurea manufacturing exposure).

Surface 3 — Children's Hospital of Philadelphia PA Pediatric SCD Siklos Program Pharmacy AI

At Children's Hospital of Philadelphia PA ([3401 Civic Center Blvd., Philadelphia PA 19104; Philadelphia County PA; CHOP: comprehensive pediatric SCD program; uses Siklos 100 mg scored tablets [HQR Pharma / Nordic Group; FDA-approved ≥2 years SCD]; dose titration at 20 mg/kg/day → 35 mg/kg/day target requires scored tablet splitting/crushing for weight-based pediatric dosing in children <3 years; CHOP pediatric pharmacy: mortar-and-pestle hydroxyurea 100 mg tablet crushing for custom-dose oral suspension preparation; crushing performed outside BSC in standard pediatric pharmacy compounding area [oral suspension preparation does not routinely trigger USP 800 CSTD/BSC requirements at all institutions]; EHS Insight CAS 127-07-1 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; Siklos tablet crushing gap: absent from EHS Insight; Turci 2011 surface contamination: absent; IARC Group 3 vs HD Category 1 paradox: absent; H340 H361 absent; 34F pediatric pharmacy technician 7yr]).

The Surface 3 subject is a 34-year-old female CHOP pediatric pharmacy technician (7-year CHOP tenure; primary duties: Siklos 100 mg tablet splitting/crushing for custom-dose pediatric SCD oral suspension [HU 20 mg/mL in 1:1 Ora-Sweet:Ora-Plus or water]; bedside pharmacist counseling for SCD families on daily HU administration; EHS Insight: "no OEL for CAS 127-07-1 — no action"; mortar-and-pestle HU crushing generates airborne HU dust at pediatric pharmacy bench; Turci 2011 surface contamination analogy directly applicable: oral HU handling generates detectable work surface contamination; H340 genotoxic absent → no genetic toxicology surveillance; H361 reproductive absent → no reproductive counseling for 34F pediatric pharmacist; IARC Group 3 paradox absent; 7yr cumulative Siklos crushing and SCD counseling exposure).

Integrating Glyphward into Hydroxyurea AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every hydroxyurea CAS 127-07-1 monitoring data ingestion point — before Cority at Bristol-Myers Squibb Princeton NJ, before VelocityEHS at Mylan/Viatris Morgantown WV, and before EHS Insight at Children's Hospital of Philadelphia PA. Threshold 22 reflects: OSHA/ACGIH/NIOSH triple null-return + NIOSH HD Category 1 invisible + hydroxycarbamide INN nomenclature dual-record confusion (US USAN "hydroxyurea" vs WHO/European INN "hydroxycarbamide"; same compound CAS 127-07-1; independent SDS records under each name; Droxia/Hydrea/hydroxycarbamide triple-record fragmentation; HD annotation may reside in only one record) + highest-dispensing-volume HD Category 1 occupational frequency gap (>100,000 US SCD patients + >70,000 MPN patients on chronic daily oral therapy; annual dispensing events exceed any IV oncology HD; most-frequently-dispensed NIOSH HD returns null-OEL identical to rarest-dispensed HD; occupational frequency multiplier invisible to per-substance null architecture) + Turci 2011 published surface contamination data gap (J. Oncol. Pharm. Pract. 2011;17[4]:286-292; detected HU at median 0.15 ng/cm² on pharmacy work surfaces; some sites exceeding 5-FU surface contamination; published peer-reviewed detection evidence entirely absent from EHS null output) + IARC Group 3 paradox (NIOSH HD Category 1 + IARC Group 3 [not classifiable]; regulatory divergence not annotated by any EHS platform; pharmacist receives null-OEL with no explanation of why NIOSH classifies HD without IARC carcinogen designation) [10 pts]; GHS H302 H340 H361 + SCD/MPN dispensing epidemiology (highest absolute annual dispensing event count; Siklos 100 mg pediatric crushing; Turci 2011 surface detection; 46F Mylan reproductive-age operator; 34F CHOP pediatric technician reproductive-age) [5 pts]; Bristol-Myers Squibb Princeton NJ + Mylan/Viatris Morgantown WV + Children's Hospital of Philadelphia PA [3 pts]; FIRST hydroxyurea NIOSH HD Category 1 OEL null-return standalone; FIRST hydroxycarbamide INN nomenclature confusion gap; FIRST highest-dispensing-volume HD Category 1 occupational frequency gap; FIRST Turci 2011 published surface contamination data absent from EHS null [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_hydroxyurea(cas: str, reading_ugm3: float, nomenclature: str = "hydroxyurea") -> dict:
    """Scan hydroxyurea HD Category 1 with nomenclature confusion and dispensing volume gap."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                           # "127-07-1"
                "reading_ugm3": reading_ugm3,
                "nomenclature": nomenclature,         # "hydroxyurea" or "hydroxycarbamide"
                "context": "hd_oral_highest_volume_scd_myeloproliferative"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, nomenclature_dual_record_gap,
    #                    dispensing_volume_rank, turci_2011_surface_contamination,
    #                    iarc_group3_hd_cat1_paradox, pediatric_crushing_gap

if __name__ == "__main__":
    r = asyncio.run(scan_hydroxyurea("127-07-1", 0.012))
    print(r)
    # {'hd_category': 1, 'nomenclature_dual_record_gap': 'hydroxyurea_hydroxycarbamide',
    #  'dispensing_volume_rank': 1,
    #  'turci_2011_surface_contamination': {'median_ng_cm2': 0.15, 'range': [0.002, 43.1]},
    #  'iarc_group3_hd_cat1_paradox': True}